.jpeg)
2026-03-18 06:00:53
Latest systematic review study finds that use of tyrosine kinase inhibitors and Janus kinase inhibitors may be associated with increased keratinocyte carcinoma risk, providing important reference for tumor drug therapy safety assessment.
2026-03-18 05:49:30
CLISGen is an innovative database platform integrating SNP genotype information from cancer cell lines, containing genetic data from over 1000 cancer cell lines, helping researchers efficiently select cell models with specific genetic variations and breaking through bottlenecks in tumor functional genomics research.
2026-03-12 07:35:33
RAS mutations account for approximately 30% of malignancies, but resistance limits clinical benefits. New research reveals sustained mTORC1 activity as a non-genetic driver of RAS inhibitor resistance. Farnesyltransferase inhibitor Dalifarnib (KO-2806) blocks mTORC1 activation via RHEB, achieving rapid durable tumor regression when combined with RAS inhibitors.
2026-03-12 07:23:51
ARID1A is a key subunit of the SWI/SNF chromatin remodeling complex, with mutations linked to various cancers. Recent research reveals ARID1A deficiency triggers viral mimicry, enhancing tumor immunogenicity and providing new immunotherapy targets.
2026-02-01 22:25:32
